<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suresh, Garbapu</style></author><author><style face="normal" font="default" size="100%">Nadh, Ratnakaram Venkata</style></author><author><style face="normal" font="default" size="100%">Srinivasu, Navuluri</style></author><author><style face="normal" font="default" size="100%">Yennity, Durgaprasad</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Convenient new and efficient commercial synthetic route for dasatinib (sprycel®)</style></title><secondary-title><style face="normal" font="default" size="100%">Synthetic Communications</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUN</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">47</style></volume><pages><style face="normal" font="default" size="100%">1610-1621</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">A new and efficient synthetic route for dual Src/Abl kinase inhibitor Dasatinib (Sprycel®), an anticancer drug, is described. This commercially viable process yields Dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity &gt;99.80% over 4 stages.</style></abstract><issue><style face="normal" font="default" size="100%">17</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">1.065</style></custom4></record></records></xml>